|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/00 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| C07K 16/22 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3624837 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18730518.0 |
| Date of filing the European patent application | 2018-05-15 | |
| (97) | Date of publication of the European application | 2020-03-25 |
| (45) | Date of publication and mention of the grant of the patent | 2025-07-30 |
| (46) | Date of publication of the claims translation | 2025-10-10 |
| (86) | Number | PCT/US2018/032757 |
| Date | 2018-05-15 |
| (87) | Number | WO 2018/213304 |
| Date | 2018-11-22 |
| (30) | Number | Date | Country code |
| 201762507053 P | 2017-05-16 | US | |
| 201762581992 P | 2017-11-06 | US |
| (72) |
COLLINS, Helen L. , US
HNATYSZYN, James , US
XIANG, Hong , US
ZHANG, Xiang , US
|
| (73) |
Five Prime Therapeutics, Inc. ,
111 Oyster Point Boulevard, South San Francisco, CA 94080,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Anti-FGFR2 antikūnai derinyje su chemoterapijos agentais vėžio gydymui |
| ANTI-FGFR2 ANTIBODIES IN COMBINATION WITH CHEMOTHERAPY AGENTS IN CANCER TREATMENT |